Infectious Disorders - Drug Targets aims to cover all the latest and outstanding developments in medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in infectious disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews and research articles written by leaders in the field covering a range of current topics on drug targets involved in infectious disorders. As the discovery, identification, characterization and validation of novel human drug targets for anti-infective drug discovery continue to grow, this journal will be essential reading for all pharmaceutical scientists involved in drug design, discovery and development.
Inflammation Research (IR) publishes peer-reviewed papers on all aspects of inflammation and related fields including histopathology, immunological mechanisms, gene expression, mediators, experimental models, clinical investigations and the effect of drugs. Related fields are broadly defined and include for instance, allergy and asthma, shock, pain, joint damage, skin disease as well as clinical trials of relevant drugs.
Bibliographic Data
First published in 1969
Renamed in 1995
1 volume per year, 12 issues per volume
+ 2 supplements, in free sequence
Format: 21 x 27.9 cm
ISSN 1023-3830 (print)
ISSN 1420-908X (electronic)
Â
Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS).Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, and arthritic conditions. The journal has five main interest areas: Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress statesRheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugsGastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agentsNeuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and painNovel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs.Requirements for manuscripts on the pharmacological or inflammatory properties of, natural products are described in the editorial Inflammopharmacology Vol. 15, issue 5 or on the journal website: www.springer.com/10787.
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.The subject material appropriate for submission includes:• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. • Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.• Agents that activate genes or modify transcription and translation within the immune response.• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.• Production, function and regulation of cytokines and their receptors.• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions. • Studies on the nature and function of drug and hormone receptors on lymphocytes and other cells in the immune system.• Studies of cell-derived or humoral factors that modify the immune system causing cytotoxicity, inducing antibody production and mediating inflammatory responses.• The development of immunologically based assays and their application to disease, including assays for drugs, hormones, cyclic nucleotides, tumor antigens, etc.• The Editors will be pleased to receive published books for possible independent review.Please Bookmark this URL: http://www.elsevier.com/locate/intimpThese Backfiles include Immunopharmacology and the International Journal of Immunopharmacology.
The International Journal for Parasitology – Drugs and Drug Resistance publishes the results of original research in the area of anti-parasite drug identification, development and evaluation, and parasite drug resistance. The journal also covers research into natural products as anti-parasitic agents, and bioactive parasite products. Studies can be aimed at unicellular or multicellular parasites of human or veterinary importance.A list showing the types of articles that are considered is included below. Original research includes the development of novel and innovative concepts and ideas, as well as experimental and observational science that raises new hypotheses. Because of its breadth of organism coverage, all contributions should include relevant information about the parasite of interest in order to be comprehensible to non-experts in the particular subject of the articles. The principal form of publication is the full length article which contains substantial results from a major program of research. The journal also accepts brief reports that have similar subject scope as the full-length article, but do not merit a full-length publication.In addition, the journal provides a medium for highlighting selected articles reporting highly significant original findings, as Editor's Choice Manuscripts. It also commissions articles with emphasis on shorter, focused Reviews of topical issues and strategically important subjects. The journal encourages critical comment and debate on matters of current controversy in the area of parasite drug resistance and anti-parasite drugs via "Current Opinions".This title is fully open access and therefore funded not through library subscription payments but through author fees. If you would like your article to be published open access, but you genuinely cannot afford these fees, then individual waiver requests are considered on a case-by-case basis and may be granted in cases of genuine need. Priority for this waiver programme will be given to applications by authors from countries eligible for the Research4Life programme (see http://www.research4life.org/institutions.html).Types of articles considered:Compound library screening for inhibitors against enzymes or whole parasitesDrug target validation (chemical and/or genetic)Drug target identification (must include some inhibitor studies rather than characterisation of an enzyme, for example)Drug structure-activity relationship studiesMechanisms of drug action and resistanceReports of the development of drug resistance both in the field and laboratoryStudies on drug toxicity to the host (either on single host cells or whole organism)Reports on toxicity in the fieldComputational approaches to drug discovery or drug-target identificationDevelopment of assays directed at screening for inhibitorsDrug combination studiesNatural products as anti-parasitic agentsBioactive products produced by parasitesUse of live parasites as immunomodulatory agentsEpidemiological aspects of the emergence and spread of parasite drug resistanceHuman clinical trials
The online-version will be updated every month before the print-version of the Clinical Nephrology will be published. Upon request we will send the password and user name by e-mail. The online-service is only available for subscribers of the print-version, if proof of purchase is submitted. The use of the online-version will be charged with an extra fee (additional to the subscription of the print-version). The service can be used until December 31st of the year of subscription.
International Journal of Clinical Pharmacy is a bi-monthly, peer-reviewed journal publishing topics in the broad field of clinical pharmacy and related subjects.
This is a transformative journal, you may have access to funding.
The rapid growth of interest in medicinal mushrooms research is matched by the large number of disparate groups that currently publish in a wide range of publications. The International Journal of Medicinal Mushrooms is the one source of information that will draw together all aspects of this exciting and expanding field - a source that will keep you up to date with the latest issues and practice. The International Journal of Medicinal Mushrooms published original research articles and critical reviews on a broad range of subjects pertaining to medicinal mushrooms, including systematics, nomenclature, taxonomy, morphology, medicinal value, biotechnology, and much more. Papers on new techniques that might promote experimental progress in the aforementioned field are also welcomed. In addition to full-length reports of original research, the journal publishes short communications and interesting case reports, together with literature reviews. Letters to the editor on topics of interest to readers are also published.
clinical application, or which provides insights into the biological basis of neuropsychiatric disorders and thereby advances their pharmacological treatment. Such research might derive from the full spectrum of biological and psychological fields of inquiry, encompassing classical and novel techniques in neuropsychopharmacology, as well as strategies such as neuroimaging, genetics, psycho-neuroendocrinology and neuropsychology. IJNP's rapid publication policy is facilitated by web-based submission and review, and the journal publishes the definitive versions of papers online, ahead of the printed issues. All papers are indexed in PubMed and Thomson Reuters Journal Citation Reports.
International Journal of Pharmacology is a peer-reviewed well indexed scientific journal dedicated to publish the significant research findings in all areas of pharmacology and related disciplines. Scope of the journal covers: behavioral pharmacology, neuro-pharmacology and analgesia, cardiovascular pharmacology, pulmonary, gastrointestinal and urogenital pharmacology, endocrine pharmacology, immune-pharmacology and inflammation and molecular and cellular pharmacology. International Journal of Pharmacology now accepting new submissions. Submit your best paper via online submission system.
The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.
Each issue contains original articles dealing with anticancer drug development. Other sections are devoted to invited review articles and letters to the editor. The journal also affords the opportunity to publish the proceedings of special workshops and symposia devoted to the development of new anticancer agents. Provided they add to the understanding of the investigational agents, the journal is not adverse to publishing clinical trials with negative results.
Investigatio
Journal for ImmunoTherapy of Cancer is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.The journal welcomes submissions in the following areas and other related topics:Basic Tumor ImmunologyTumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions with the anti-tumor immune responseClinical/Translational Cancer ImmunotherapyFirst-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcomeImmunotherapy BiomarkersPredictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studiesReviews/EditorialsTriggering discussion on hot topics and innovative concepts
Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC). The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals that was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of biological therapies, including immunotherapy, for patients with cancer. SITC is the world's leading member society of medical professionals dedicated to advancing cancer immunotherapy through its initiatives, educational sessions, and collaborative endeavors. The society has become THE forum for innovative discussions in the field.